Skip to main content
Skip to footer
Home
About
About
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Pipeline
Pipeline
Vidofludimus Calcium
IMU-856
IMU-381
News
Publications
Investors
IR Home
News Releases
Events and Presentations
Stock Information
Financials and SEC Filings
Corporate Governance
IR Contact
Career
Contact
Home
About
About
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Pipeline
Pipeline
Vidofludimus Calcium
IMU-856
IMU-381
News
Publications
Investors
IR Home
News Releases
Events and Presentations
Stock Information
Financials and SEC Filings
Corporate Governance
IR Contact
Career
Contact
MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting
Friday, September 11, 2020 – Sunday, September 13, 2020
Poster MSVirtual2020
Play Recording MSVirtual2020
Next Post
IMU-838 Phase 2 Data EMPhASIS Trial in RRMS
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro
Home – 2
About
Pipeline
News
Publications
Investors
Career
Contact
Management
Board of Directors
Scientific-Medical
Advisory Board
Company Values
Vidofludimus Calcium
IMU-856
IMU-381
IR Home
News Releases
Events and Presentations
Stock Informations
Financials and SEC Filings
Corporate Governance
IR Contact
Search ...
Search
